CL
CLNN
Clene Inc.
$5.84
+5.61%
$74.6M
No data for this timeframe.
Vol
Market Cap$74.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders11 funds
Inst. Value$2.5M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 24S
Insider Net $-$2.8M
Reddit Sentiment50° Neutral
SEC Reports7
Press Releases1
Recent Activity
May 21, 2026
Insider
Gay Jonathon was granted 1,500 shares
Director
May 21, 2026
Insider
WILCOX REED N was granted 1,500 shares
Director
May 21, 2026
Insider
Kiernan Matthew was granted 1,500 shares
Director
May 14, 2026
SEC
Clene reported Q1 2026 results with total revenue of $15K (down 81% YoY from $81K) and a net loss of $8.1M ($0.69/share)
8-K — Impact 6/10
May 14, 2026
SEC
Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven by $6.0M in other ex
PRESS-RELEASE — Impact 6/10
May 5, 2026
SEC
Clene Inc. is offering 1,000,000 shares of common stock at $7.00 per share, a 13.5% discount to the $8.09 closing price
424B5 — Impact 7/10
Inst.
BlackRock, Inc. — DOUBLED
33,852 shares ($198.7K)
Inst.
STATE STREET CORP — DOUBLED
29,801 shares ($174.9K)
Price Targets
$32.20
+451.4% upside
Strong Buy
Current $5.84
Low $20.00
Median $30.00
High $50.00
5 analysts
$20.00
$50.00
Analyst Ratings
2Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 4, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 12, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Jan 9, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 ▲ +20.0% | $-0.30 — $-0.22 | 70% YoY | 2 |
| Next Q | $-0.28 ▲ +5.1% | $-0.34 — $-0.22 | 54% YoY | 2 |
| Current FY | $-1.41 ▲ +15.9% | $-1.55 — $-1.26 | 45% YoY | 2 |
| Next FY | $-1.79 ▼ -23.0% | $-3.21 — $-0.37 | -27% YoY | 2 |
Latest Reports
MIXED
8-K
6/10
Clene reported Q1 2026 results with total revenue of $15K (down 81% YoY from $81K) and a net loss of $8.1M ($0.69/share)
May 14, 2026
BEARISH
PRESS-RELEASE
6/10
Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven by $6.0M in other ex
May 14, 2026
MIXED
Press
7/10
Clene Inc. reported its 2025 financial results, highlighted by a 33% reduction in net loss to $26.2 million and an overs
Mar 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.5M | — |
| PEAK6 LLC | $246.6K | — |
| VANGUARD FIDUCIARY TRUST CO | $215.5K | — |
| BlackRock, Inc. | $166.6K | DOUBLED |
| STATE STREET CORP | $146.9K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Gay Jonathon | A | $0.00 |
| May 21, 2026 | WILCOX REED | A | $0.00 |
| May 21, 2026 | Kiernan Matthew | A | $0.00 |
| May 21, 2026 | Jacobovitz Shalom | A | $0.00 |
| May 21, 2026 | MATLIN DAVID | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
11 institutional holders with $2.5M total value (505,346 shares) as of 2026-Q1. Top holders: VANGUARD, PEAK6, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 308,230 | $1.5M | 61.0% | — |
| 2 | PEAK6 LLC | 50,012 | $246.6K | 9.9% | — |
| 3 | VANGUARD FIDUCIARY TRUST CO | 43,715 | $215.5K | 8.7% | — |
| 4 | BlackRock, Inc. | 33,799 | $166.6K | 6.7% | DOUBLED +711.6% |
| 5 | STATE STREET CORP | 29,801 | $146.9K | 5.9% | DOUBLED +138.4% |
| 6 | MORGAN STANLEY | 19,832 | $97.8K | 3.9% | — |
| 7 | WELLS FARGO & COMPANY/MN | 5,927 | $29.2K | 1.2% | ADD +39.6% |
| 8 | Vanguard Global Advisers, LLC | 5,609 | $27.7K | 1.1% | — |
| 9 | JONES FINANCIAL COMPANIES LLLP | 5,000 | $23.6K | 0.9% | — |
| 10 | PNC FINANCIAL SERVICES GROUP, INC. | 2,735 | $13.5K | 0.5% | — |
| 11 | GROUP ONE TRADING LLC | 686 | $3.4K | 0.1% | TRIM -57.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 4,171 | 33,852 | +711.6% | $198.7K | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 12,501 | 29,801 | +138.4% | $174.9K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 4,247 | 5,927 | +39.6% | $34.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 67 | 122 | +82.1% | $716.00 | 2025-Q4 |
| FMR LLC | DOUBLED | 1 | 48 | +4700.0% | $282.00 | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 1,701 | 719 | -57.7% | $4.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 1,678 | 15 | -99.1% | $90.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 133,334 | 188,357 | +41.3% | $736.5K | 2025-Q2 |
| UBS Group AG | DOUBLED | 310 | 1,678 | +441.3% | $6.6K | 2025-Q2 |
| UBS Group AG | DOUBLED | 9 | 310 | +3344.4% | $955.00 | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 114 | 46 | -59.6% | $244.00 | 2024-Q4 |
9 unique insiders with 39 transactions. Net insider value: -$2.8M ($0.00 bought, $2.8M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Gay Jonathon | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | WILCOX REED N | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | Kiernan Matthew | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | Jacobovitz Shalom | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | MATLIN DAVID J | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | Mosca Alison | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | Desai Arjun JJ | Director | AWARD | 1,500 | — | — |
| May 21, 2026 | McLaughlin Vallerie | Director | AWARD | 1,500 | — | — |
| May 12, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 73,296 | $6.20 | $454.4K |
| May 11, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 22,177 | $6.75 | $149.7K |
| May 4, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 72,884 | $6.80 | $495.6K |
| May 1, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,795 | $6.01 | $34.8K |
| Apr 30, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,736 | $6.08 | $34.9K |
| Apr 29, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 12,170 | $5.63 | $68.5K |
| Apr 28, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 1,591 | $5.90 | $9.4K |
| Apr 21, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 61,345 | $6.14 | $376.7K |
| Apr 20, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 4,318 | $6.12 | $26.4K |
| Apr 17, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 25,040 | $6.43 | $161.0K |
| Apr 16, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 7,748 | $6.40 | $49.6K |
| Apr 15, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 6,374 | $6.48 | $41.3K |
| Apr 2, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 24,925 | $4.81 | $119.9K |
| Apr 1, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 4,278 | $4.97 | $21.3K |
| Mar 31, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 67,991 | $4.88 | $331.8K |
| Mar 30, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 15,536 | $5.10 | $79.2K |
| Mar 27, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 17,470 | $4.75 | $83.0K |
| Mar 26, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,319 | $5.40 | $28.7K |
| Mar 25, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 7,098 | $5.50 | $39.0K |
| Mar 24, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,492 | $5.78 | $31.7K |
| Feb 19, 2026 | Jacobovitz Shalom | Director | AWARD | 4,098 | — | — |
| Feb 19, 2026 | McLaughlin Vallerie | Director | AWARD | 3,030 | — | — |
| Feb 19, 2026 | Mosca Alison | Director | AWARD | 4,201 | — | — |
| Feb 19, 2026 | MATLIN DAVID J | Director | AWARD | 5,372 | — | — |
| Feb 19, 2026 | Desai Arjun JJ | Director | AWARD | 3,168 | — | — |
| Feb 19, 2026 | Kiernan Matthew | Director | AWARD | 2,755 | — | — |
| Feb 19, 2026 | Gay Jonathon | Director | AWARD | 3,271 | — | — |
| Feb 3, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,559 | $4.10 | $22.8K |
| Feb 2, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 3,800 | $4.04 | $15.4K |
| Jan 30, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 5,686 | $4.13 | $23.5K |
| Jan 29, 2026 | Ugwumba Chidozie | 10%+ Owner | SELL | 15,284 | $4.32 | $66.0K |
7 SEC filing reports analyzed. Sentiment: 3 bullish, 2 bearish, 1 mixed, 1 neutral. Avg impact: 6.4/10.
MIXED
8-K
6/10
Clene reported Q1 2026 results with total revenue of $15K (down 81% YoY from $81K) and a net loss of
May 14, 2026
BEARISH
PRESS-RELEASE
6/10
Clene reported Q1 2026 EPS of -$0.69 (GAAP), a significant miss versus the -$0.50 consensus, driven
May 14, 2026
BEARISH
424B5
7/10
Clene Inc. is offering 1,000,000 shares of common stock at $7.00 per share, a 13.5% discount to the
May 5, 2026
BULLISH
8-K
8/10
Clene Inc. announces FDA agreement that its CNM-Au8 data may support accelerated approval NDA for AL
May 4, 2026
NEUTRAL
DEFA14A
3/10
Clene Inc. filed a definitive proxy statement for an upcoming shareholder vote, which is a routine r
Apr 10, 2026
BULLISH
8-K
7/10
Clene Inc. entered into a $8.04 million subaward agreement with New York University (NYU) for the th
Mar 17, 2026
BULLISH
8-K
8/10
Clene Inc. reported its full year 2025 financial results, showing reduced net loss and operating exp
Mar 12, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 2 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$32.20 mean target
+451.4% upside
Strong Buy (3.00)
$20.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $5.84 |
| Target Low | $20.00 |
| Target Mean | $32.20 |
| Target Median | $30.00 |
| Target High | $50.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.30 | $-0.22 | 70.4% | +20.0% | — | $0.0B | 80.7% | 2 |
| Next Q 2026-09-30 |
$-0.28 | $-0.34 | $-0.22 | 54.0% | +5.1% | — | $0.0B | 292.0% | 2 |
| Current FY 2026-12-31 |
$-1.41 | $-1.55 | $-1.26 | 45.2% | +15.9% | 0↑ 1↓ | $0.0B | 3.7% | 2 |
| Next FY 2027-12-31 |
$-1.79 | $-3.21 | $-0.37 | -27.4% | -23.0% | 0↑ 1↓ | $0.0B | 11300.3% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.260 | |
| 7d ago | $-0.260 | |
| 30d ago | $-0.325 | +0.065 |
| 60d ago | $-0.325 | +0.065 |
| 90d ago | $-0.740 | +0.480 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 4, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 12, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 9 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 2 | 10 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
CLNN, upcoming big gainer in the stock market?
▲ 1
💬 1
⚡ 0.5
May 14, 2026
earnings
Clene Reports First Quarter 2026 Financial Results and Recent Operating Highlights
<p>SALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary
May 13, 2026
earnings_calendar
CLNN Q1 2026 Earnings Scheduled — 2026-05-13
May 5, 2026
other
Clene Announces $7 Million Underwritten Offering of Common Stock
<p>SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly
May 5, 2026
other
Clene to Present at Upcoming May Conferences
<p>SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary
May 5, 2026
short_volume
Short Volume: CLNN — 56.6% short (0.3M / 0.6M)
Short: 343,300 | Exempt: 22,885 | TRF Vol: 606,251 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 5, 2026
short_interest
FTD: CLNN — 470,570 shares ($3.8M) failed to deliver
Settlement: 20260505, Price: $8.09, FTD Value: $3,806,911.3, CLENE INC COM NEW
May 5, 2026
earnings_calendar
CLNN Q1 2026 Earnings Scheduled — 2026-05-05
May 4, 2026
short_volume
Short Volume: CLNN — 58.4% short (2.9M / 5.0M)
Short: 2,895,424 | Exempt: 24,497 | TRF Vol: 4,958,158 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
Clinical Trial
An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: CNMAu8 (Phase 2)
Trial: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Asses
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: CNMAu8 (Phase 2)
Trial: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Asses
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: CNMAu8 (Phase 2)
Trial: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Asses
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: CNMAu8 (Phase 2)
Trial: An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Asses
Mar 12, 2026
earnings
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
<p>SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidia